Pain Therapeutics
Current and Future Treatment Paradigms
Seiten
2013
Royal Society of Chemistry (Verlag)
978-1-84973-645-9 (ISBN)
Royal Society of Chemistry (Verlag)
978-1-84973-645-9 (ISBN)
This book presents a contemporary review of the field of Pain Therapeutics, including the historical medicines which still dominate standard of care treatments, as well as new mechanisms and combinations/reformulations that have dominated the regulatory approvals over the last decade.
This book presents a contemporary review of the field of Pain Therapeutics, including the historical medicines which still dominate standard of care treatments, as well as the new mechanisms and combinations/reformulations that have dominated the regulatory approvals over the last decade. In addition this book provides a deep review of the key biological mechanisms currently under investigation for their utility into the treatment of pain, such as ion channels, opiates and others.
Additional discussion highlights the current challenges of pain research, covering a range of topics from difficulties in identifying new targets from pre-clinical models to the current regulatory and commercial challenges. This background sets the scene for recent scientific changes in pain research, such as the drive for genetic validation of targets and the derivation of human cell platforms from stem cells. Finally the book covers the discovery and development stories for two pain products approved in the last decade. These case studies for Lyrica and the Butrans patch, give insight into the discovery and development challenges and successes for both an oral and non-oral product.
This book presents a contemporary review of the field of Pain Therapeutics, including the historical medicines which still dominate standard of care treatments, as well as the new mechanisms and combinations/reformulations that have dominated the regulatory approvals over the last decade. In addition this book provides a deep review of the key biological mechanisms currently under investigation for their utility into the treatment of pain, such as ion channels, opiates and others.
Additional discussion highlights the current challenges of pain research, covering a range of topics from difficulties in identifying new targets from pre-clinical models to the current regulatory and commercial challenges. This background sets the scene for recent scientific changes in pain research, such as the drive for genetic validation of targets and the derivation of human cell platforms from stem cells. Finally the book covers the discovery and development stories for two pain products approved in the last decade. These case studies for Lyrica and the Butrans patch, give insight into the discovery and development challenges and successes for both an oral and non-oral product.
Pfizer Inc., USA
The Disease of Pain and Current Market Trends;
Oral Opiods;
Anti-inflammatory drugs;
Ion Channel Modulators;
Neurotransmitters and Other Non-Opiate Central Mechanisms;
Biotherapeutics for the Treatment of Pain;
Peptide Therapeutics from Venomous Creatures;
Non Oral Treatments for Pain;
Affective and Cognitive Modulation of Pain;
Pain Management Companies;
Enabling Next Generation Pain Therapeutics through Precision Medicine;
Case study - Discovery and Development of Pregabalin;Case Study - Discovery and Development of the Butrans Patch
Reihe/Serie | Drug Discovery ; Volume 35 |
---|---|
Verlagsort | Cambridge |
Sprache | englisch |
Maße | 156 x 234 mm |
Gewicht | 782 g |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie |
Naturwissenschaften ► Chemie | |
Technik | |
ISBN-10 | 1-84973-645-6 / 1849736456 |
ISBN-13 | 978-1-84973-645-9 / 9781849736459 |
Zustand | Neuware |
Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Arzneimittelverzeichnis für Deutschland (einschließlich …
Buch | Hardcover (2024)
Rote Liste Service GmbH (Verlag)
109,00 €
Englisch für Apotheker und PTAs
Buch | Spiralbindung (2024)
Kohlhammer (Verlag)
32,00 €